tradingkey.logo

BUZZ-Amgen falls after FDA's clinical hold on weight-loss drug study

ReutersFeb 4, 2025 9:19 PM

Drugmaker Amgen's AMGN.O shares fall 2.8% to $281 in extended trading

Company says U.S. FDA placed a clinical hold on an early-stage study for its experimental weight-loss drug AMG 513

Amgen says discussions are underway on a path forward to reopen the study

Company posts Q4 adj profit of $5.31/shr vs analysts' average est. of $5.08/shr - LSEG

Up to last close, stock down 10.2% in the last 12 months

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI